Therapeutic role of mobilized bone marrow cells children with non ischemic dilated cardiomyopathy

Abstract

Dilated cardiomyopathy is an important cause of congestive cardiac failure in infants and children. Mobilizing hematopoietic progenitor cells is a promising intervention to this deadly disease. Aim of the work: to evaluate the granulocyte colony stimulating factor (GCSF) as a therapeutic modality in children with idiopathic dilated cardiomyopathy (IDCM). subjects and methods: This case control prospective study was conducted on 20 children with IDCM following up at cardiology clinic Children’s Hospital, Ain shams university (group 1) who were compared to another ten age, sex, duration of illness and systolic function matched children with IDCM as a control group (group 2). They were subjected to history taking, clinical Examination, echocardiographic study of the left ventricle and cluster of differentiation thirty four T (CD34+) cells assessment in peripheral blood before and one week after granulocyte colony stimulating factor intake for five consecutive days by group1. GCSF was not given to group 2. Results: a significant improvement in echocardiographic data and increase of the CD34+T cells was found in group 1 patients post granulocyte colony stimulating factor intake one week after GCSF intake and for the next 6 months but not in group 2. The percentage of change of the CD34+T cells showed no significant correlation with the percentage of change of the left ventricular dimensions and systolic function. Administration of GCSF to children with IDCM resulted in clinical and echocardiographic improvement that was not correlated to the mobilized cluster of differentiation thirty four T cells, implying the involvement of additional mechanisms than simple stem cell mobilization.